RxDoctor Payments Data

Jonathan Rouse, DPM

Foot & Ankle Surgery · Omaha, NENPI 1003250556

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Stryker accounts for 79.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $7,474 and has fallen 73.4% since, to $1,990 in 2025.

$20,152in general payments, 2019–2025

Across 250 payments — averaging $80.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$16K
  • Treace Medical Concepts, Inc.$2K
  • Smith+Nephew$836
  • Organogenesis Inc.$491
  • Medical Device Business Services, Inc.$303
  • Musculoskeletal Transplant Foundation Inc.$222
  • plus $703 from 18 others

What the payments were for

  • Travel & lodging$8,24641%
  • Food & beverage$11,60358%
  • Education$3032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,152 in reported general payments places this provider in the 75th percentile of 43 foot & ankle surgery providers in Nebraska.

See all foot & ankle surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,014,774
Medicare patients
529
Services billed
6,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pregabalin12$822
Gabapentin33$368
Doxycycline Hyclate15$225
Clotrimazole12$220
Methylprednisolone24$156

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →